Lead Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Age

18 - 76 years

Sex

ALL

Healthy Volunteers

No

•Are SCLE, DLE and/or SLE that have completed the 24 week Treatment of the Willow Study
•Have a Body Mass Index (BMI) within the less than or equal to (\<=) 40 kilograms per meter square (inclusive) at Screening
•Participants who had successfully completed Week 48 of the Part 1 will have the opportunity to participate in the LTE Part 2. In exceptional cases and after Sponsor review, participants who have completed the Week 48 visit of the Part 1 within the previous 4-weeks may be considered for Part 2 participation based on eligibility review. Previous 4-weeks will be calculated from the Week 48 visit of Part 1

•Participants who experienced serious event(s) related to the study intervention during the WILLOW study
•Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Long Term Extension (LTE) study participation
•Ongoing or active clinically significant viral (including Severe acute respiratory syndrome coronavirus 2 \[(SARS-CoV-2)\], bacterial or fungal infection, or any major episode of infection requiring hospitalization
•Received LTE prohibited medication during the WILLOW study or after the WILLOW study Week 24
•Participation in any other investigational drug study after the WILLOW study Week 24

Related studies

NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more

NCT06875960 · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT06335979 · Systemic Lupus Erythematosus, SLE

NCT06647069 · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)

NCT07371468 · Systemic Lupus Erythematosus

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)